Suppressive Effects on the Immune Response and Protective Immunity to a JEV DNA Vaccine by Co-administration of a GM-CSF-Expressing Plasmid in Mice by Chen, Hui et al.
Suppressive Effects on the Immune Response and
Protective Immunity to a JEV DNA Vaccine by Co-
administration of a GM-CSF-Expressing Plasmid in Mice
Hui Chen, Na Gao, Dongying Fan, Jiangman Wu, Junping Zhu, Jieqiong Li, Juan Wang, Yanlei Chen,
Jing An*
Department of Microbiology, School of Basic Medical Sciences, Capital Medical University, Beijing, People’s Republic of China
Abstract
As a potential cytokine adjuvant of DNA vaccines, granulocyte-macrophage colony–stimulating factor (GM-CSF) has
received considerable attention due to its essential role in the recruitment of antigen-presenting cells, differentiation and
maturation of dendritic cells. However, in our recent study of a Japanese encephalitis virus (JEV) DNA vaccine, co-inoculation
of a GM-CSF plasmid dramatically suppressed the specific IgG response and resulted in decreased protection against JEV
challenge. It is known that GM-CSF has been used in clinic to treat neutropenia for repopulating myeloid cells, and as an
adjuvant in vaccine studies; it has shown various effects on the immune response. Therefore, in this study, we characterized
the suppressive effects on the immune response to a JEV DNA vaccine by the co-administration of the GM-CSF-expressing
plasmid and clarified the underlying mechanisms of the suppression in mice. Our results demonstrated that co-
immunization with GM-CSF caused a substantial dampening of the vaccine-induced antibody responses. The suppressive
effect was dose- and timing-dependent and likely related to the immunogenicity of the antigen. The suppression was
associated with the induction of immature dendritic cells and the expansion of regulatory T cells but not myeloid-derived
suppressor cells. Collectively, our findings not only provide valuable information for the application of GM-CSF in clinic and
using as a vaccine adjuvant but also offer further insight into the understanding of the complex roles of GM-CSF.
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Introduction
In recent years, DNA vaccines have attracted much attention
for their ability to induce both humoral and cellular immune
responses. Nevertheless, despite their significant advantages, DNA
vaccines have only shown limited success in animal models
because of their low immunogenicity. Thus, to improve the
efficacy of DNA vaccines, a number of strategies, especially the use
of cytokine adjuvants, have been actively explored. Moreover, co-
immunization strategies with plasmids expressing cytokines, such
as interleukin (IL)-2, IL-4, IL-12, interferon (IFN)-c, tumor
necrosis factor (TNF)-a and granulocyte-macrophage colony–
stimulating factor (GM-CSF) [1,2,3,4,5], or plasmids expressing
co-stimulatory molecules [6] have been evaluated extensively with
numerous DNA vaccines. Among these cytokines, GM-CSF has
been the primary choice for many studies due to its essential role in
the recruitment of antigen-presenting cells (APCs) and in the
differentiation and maturation of dendritic cells (DCs) [5,7,8,9].
However, as an adjuvant, various roles of GM-CSF have been
reported: it appeared to help generate an immune response in
some studies but had no effect or even an inhibitory effect in
others. For example, in our recent study on a Japanese encephalitis
virus (JEV) DNA vaccine, we unexpectedly found that co-injection
of the GM-CSF plasmid significantly suppressed the specific IgG
response and led to decreased protection against JEV challenge
[10]. Similarly, a suppressive effect of the GM-CSF plasmid was
also observed by a study of a human immunodeficiency virus
(HIV) DNA vaccine, in which high levels of type I IFN at the local
inoculation site involved in this process were discovered [11]. In a
multi-center randomized trial of a melanoma vaccine, the CD8
+
and CD4
+ T cell responses were lower with the co-administration
of recombinant GM-CSF [12]. Remarkably, a randomized study
of 133 cancer patients treated with a trivalent influenza vaccine
with GM-CSF administered at a dose of 250 mg also failed to show
an increased immune response [13]. These data indicate that co-
administration of GM-CSF failed to amplify the immune response
and it even had a suppressive effect, which challenges the potential
of using GM-CSF as a vaccine adjuvant and raises concerns that it
might be harmful.
It is known that the GM-CSF receptor is expressed on CD34
+
progenitor cells, all myeloid lineages and vascular endothelial cells.
GM-CSF can promote myeloid differentiation, and it was initially
discovered as a factor with the ability to generate both
granulocytes and macrophage colonies from bone marrow
precursor cells. Until now, GM-CSF has been routinely used in
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chemo/radiotherapy cancer patients or post-bone marrow trans-
plantation patients [14]. However, GM-CSF showed opposite
functions as an adjuvant or therapeutic agent. Based upon the
contradictory findings regarding immune response and clinical
outcome, the use of GM-CSF in select treatments and adjuvant
candidates must be performed with a great deal of caution. Thus,
to provide more useful information for safe and reasonable clinical
application, it is necessary to investigate the properties of the
suppressed effects and to clarify the mechanism behind the
phenomenon.
Recent studies have demonstrated that several factors contrib-
ute to immune suppression, including DCs, regulatory T cells
(Tregs) and myeloid-derived suppressor cells (MDSCs). DCs are
professional APCs that process and present foreign- as well as self-
antigens and secrete a variety of cytokines and chemokines to
initiate and regulate immune responses to ensure immunological
homeostasis [15,16]. The strength and nature of the immune
response elicited by DCs depend on certain factors, including the
type of antigens and the subset and maturation status of DCs.
Generally, upon antigen presentation, mature DCs potently
induce an efficient primary T cell response and differentiation of
effector cells, whereas immature or semimature DCs are related to
immune tolerance through the induction of Tregs or deletion of
responding T cells [17,18]. The maturation status of DCs is
determined by the expression of surface molecules, such as CD40,
CD80, CD86 and major histocompatibility complex (MHC) II
and is also mediated by the production of some immune inhibitory
factors, such as IL-10 and Tregs [19]. Tregs play a critical role in
the maintenance of peripheral self-tolerance. They naturally
express Foxp3, a transcription factor required for the establish-
ment and maintenance of the Treg lineage identity and suppressor
function. On one hand, Tregs influence all major subpopulations
of APCs, including DCs, by the down-regulation of their antigen
presenting function and the up-regulation of immunosuppressive
cytokines. On the other hand, the functional state of DCs is
important in determining Treg biology. The mutual interaction of
DCs and Tregs may be crucial for the maintenance of peripheral
tolerance [20]. To modulate DC function, GM-CSF has been used
to induce semimature DCs that recruit Tregs, thereby preventing
autoimmune thyroiditis, myasthenia gravis and type 1 diabetes in
non-obese diabetic mice [21,22,23].
In addition, MDSCs isolated from spleen and bone marrow
have been recently reported as a new mechanism for immuno-
suppression in a wide variety of unrelated pathologic conditions
[24]. In mice, these cells are fairly well characterized as
CD11b
+Gr-1
+. It has been demonstrated that large amounts of
GM-CSF may be responsible for the expansion of the myeloid cell
pool in secondary lymphoid organs, which in turn can recruit
Tregs and thereby result in the suppressive effects on the immune
response against tumors or infections [25,26]. Thus, in the present
study, we characterized the effect of the co-administration of a
GM-CSF plasmid on the immune response induced by a JEV
DNA vaccine expressing prM-E. We also investigated if GM-CSF
affects the immune suppression by modulating the maturation
status and function of DCs or inducing Tregs by a process that
involves MDSCs. Our results indicate that co-inoculation of the
JEV prM-E antigen with GM-CSF causes substantial dampening
of the vaccine-induced immune responses and poor protection
against lethal JEV challenge, and it is associated with the induction
of immature DCs and the expansion of CD4
+CD25
+Foxp3
+ Tregs
but not MDSCs. Taken together, our findings not only provide
valuable information for the clinical application of GM-CSF but
also offer further insight into the understanding of the complex
versatility of GM-CSF.
Results
Co-inoculation of the GM-CSF plasmid suppressed
antibody (Ab) responses induced by the prM-E plasmid
DNA plasmids expressing premembrane and envelope (prM-E)
genes of JEV, dengue virus serotype 1 (DENV1) and DENV2 were
constructed in this study and named pCAG-JME, pCAG-D1ME
and pCAG-D2ME, respectively. Similarly, DNA plasmids encod-
ing the core (C) and envelope1 (E1) genes of the hepatitis C virus
(HCV) were constructed and named pCAG-HCV-C and pCAG-
HCV-E1, respectively. The plasmid encoding the murine GM-
CSF fragment was named pCAG-GM. All plasmids were
confirmed (data not shown) and purified for immunization.
BALB/c mice were vaccinated with 100 mg plasmid by
intramuscular (i.m.) injection three times at three-week intervals
(0, 3 and 6). Mice sera were collected before or after
immunizations to analyze the dynamics of the Ab response by
enzyme-linked immunosorbent assay (ELISA) (Figure 1). As
expected, the Ab levels, as measured by OD values, in the group
inoculated with pCAG-JME and pCAGGSP7 were dramatically
increased three weeks after the prime vaccination and were then
greatly enhanced following the double booster immunization.
However, Ab levels in mice co-administered with the GM-CSF
gene were significantly lower than that of the pCAG-JME+p-
CAGGSP7 group, even following the second and third immuni-
zations (p,0.01).
Meanwhile, serum samples obtained three weeks after the final
immunization were also measured for end-point titers by anti-JEV
IgG ELISA (Figure 2). Mice receiving the pCAG-JME and
pCAGGSP7 plasmids showed high anti-JEV levels, with a
geometrical mean titer (GMT) of approximately 1:14,700.
However, co-immunization of pCAG-GM with pCAG-JME
showed an inhibitory effect on specific Ab production, with a
low GMT of only up to 1:1838. There was a significant difference
between the pCAG-JME+pCAGGSP7 group and the pCAG-
JME+pCAG-GM group (p,0.01).
Figure 1. Dynamics of the Ab response of JEV DNA-immunized
mice were detected by ELISA. Booster administrations were
performed at week 3 and 6. Pre- and post-immunization serum samples
(n=10, 1:800) were collected and then Ab titers were determined. The
bar graph shows the mean 6 standard deviation (SD) values for optical
density (OD) of the group vaccinated with plasmids: gray-colored bars,
mice co-inoculated with 50 mg pCAG-JME and 50 mg pCAG-GM; black
bars, mice inoculated with a mixture of 50 mg pCAG-JME and 50 mg
pCAGGSP7; hollow bars, mice inoculated with 100 mg pCAGGSP7 empty
vector alone (*, p,0.05; **, p,0.01, one-way ANOVA test).
doi:10.1371/journal.pone.0034602.g001
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GM-CSF was related to antigens expressed by co-immunized
DNA vaccines, immunogens from other viruses in the Flaviviridae
family were used to co-immunize mice with pCAG-GM, and
serum samples were also evaluated for end-point titers by anti-
DENV or anti-HCV IgG ELISA (Figure 2). The data showed that
mice receiving the pCAG-D1ME or pCAG-D2ME and
pCAGGSP7 plasmids had similar specific Ab levels, with GMTs
of approximately 1:3200. In contrast, mice co-inoculated with
pCAG-GM and pCAG-D1ME or pCAG-D2ME induced low Ab
levels, with GMTs of only up to 1:1600 (p,0.01) and 1:2111
(p,0.05). Surprisingly, in contrast to above results, co-inoculation
with pCAG-GM showed an enhancing trend of the immune
responses induced by pCAG-HCV-C or pCAG-HCV-E1, with
GMTs of 1: 527 (HCV-C) or 1:857 (HCV-E1), which were slightly
higher than the GMTs (1: 460 for HCV-C or 606 for HCV-E1) in
groups co-inoculated with pCAGGSP7. These results indicated
that the suppressive effect of GM-CSF on the vaccine-induced
immune response with the co-inoculation was likely related to the
immunogens used in immunization, at least for the Flaviviridae
family.
To further evaluate the strength of the immune responses in
mice immunized with different DNA plasmids, anti-JEV Ab levels
were evaluated by indirect immunofluorescence assay (IFA)
(Figure 3). Intense fluorescence in the cytoplasm was observed in
the pCAG-JME+pCAGGSP7 group (Figure 3A), and it was
similar to that of the positive control (Figure 3B), in which the cells
were probed with JEV E glucoprotein monoclonal Ab (mAb).
However, the pCAG-JME+pCAG-GM group showed very weak
fluorescence in the cytoplasm (Figure 3C). Serum from
pCAGGSP7-immunized (Figure 3D) mice failed to show any
specific fluorescence. Consistent with the results of the ELISA, the
pCAG-JME+pCAGGSP7 group induced an effective Ab re-
sponse, whereas pCAG-JME+pCAG-GM did not, further indi-
cating that co-inoculation of GM-CSF suppressed the immune
response induced by pCAG-JME.
Serum levels of the JEV-specific IgG isotypes were also
determined to further assess the efficacy of the DNA vaccine
and the GM-CSF gene in the induction of Th1- or Th2-like
immune responses. The amount of JEV-specific IgG1 and IgG2a
subtypes were markedly augmented in the groups with or without
pCAG-GM, compared to the control group (pCAGGSP7 alone)
(Figure 4). Further, the IgG2a/IgG1 ratio in the control group was
approximately 1, whereas the ratios in groups of immunized mice
either with or without pCAG-GM were decreased, with ratios of
0.61360.045 and 0.73460.057, respectively, indicating the
participation of Th2 cells in the response to JEV prM-E proteins.
However, there was no statistic difference between the IgG2a/
IgG1 ratios of the pCAG-JME+pCAG-GM group and the pCAG-
JME+pCAGGSP7 group, suggesting that the balance of Th1 and
Th2-associated immunity might be not affected by the co-injection
of GM-CSF.
Figure 2. Co-inoculation of GM-CSF plasmid showed the influence on the vaccine-induced Ab responses. Sera were collected from
immunized mice (n=5) three weeks after the final vaccination. The end-point titers of anti-prM-E Abs were measured by ELISA and recorded as
geometrical mean titers (GMT). Gray bars, mice co-inoculated with 50 mg pCAG-GM and 50 mg pCAG-JME (JEV), pCAG-D1ME (DENV1), pCAG-D2ME
(DENV2), pCAG-HCV-C (HCV-C) or pCAG-HCV-E1 (HCV-E1); hollow bars, mice inoculated with a mixture of 50 mg pCAG-JME, pCAG-D1ME, pCAG-D2ME
and 50 mg pCAGGSP7 (*, p,0.05; **, p,0.01, t test).
doi:10.1371/journal.pone.0034602.g002
Figure 3. JEV-infected Vero cells reacted with DNA-immunized
mice sera and visualized by IFA. Mice sera were obtained three
weeks after the final immunization. (A) Serum from mouse immunized
with pCAG-JME+pCAGGSP7. (B) Mouse anti-JEV E glycoprotein mAb as
a positive control. (C) Serum from mouse immunized with pCAG-
JME+pCAG-GM. (D) Serum from mouse immunized with pCAGGSP7.
The figures shown are representative of five independent experiments
performed. The scale bar is 50 mm.
doi:10.1371/journal.pone.0034602.g003
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vaccine was diminished by adjuvant treatment with the
GM-CSF plasmid
BALB/c mice were vaccinated with plasmids three times and
intraperitoneally challenged three weeks post-immunization with
50 LD50 of the JEV Beijing-1 strain. As shown in Figure 5, all
mice in the pCAG-JME+pCAGGSP7 group survived the JEV
challenge, whereas mice co-immunized with the GM-CSF plasmid
were not fully protected, with a 50% survival rate (four of eight,
p,0.05), which is consistent with the low JEV-specific IgG level.
Mice immunized with pCAGGSP7 alone were not protected
(negative control). This result demonstrated that using the murine
GM-CSF gene as an adjuvant to JEV prM-E DNA immunization
hampered the ability of the vaccine to expand the protective
immunity.
The suppressive effect of pCAG-GM was dose-dependent
To determine if the suppressive effect of GM-CSF was related to
its expressed amount, mice were inoculated with various doses of
pCAG-GM (10, 25 and 50 mg) or pCAGGSP7 (50 mg) without
booster and then the expression level of GM-CSF in the serum was
monitored by ELISA at different time points as indicated. As
shown in Figure 6A, expression of GM-CSF gradually increased,
the peak value was seen on day 5 after inoculation and then it
decreased during observed period. The highest concentrations of
GM-CSF in 10, 25 and 50 mg groups were 46.4665.88,
67.36611.81 and 105.84614.58 pg/ml respectively, and they
showed significant difference (p,0.01). This indicated that the
expression levels of GM-CSF were closely associated with the
inoculated amounts. To investigate if the suppressive effect of GM-
CSF was dose-dependent, groups of mice were immunized with
50 mg pCAG-JME plasmid plus various doses of pCAG-GM (10,
25 and 50 mg) or pCAGGSP7 (50 mg), followed by two boosters at
three-week intervals. The end-point titers were measured three
weeks after the final immunization. Animals treated with 100 mg
pCAGGSP7 served as a control. As shown in Figure 6B, co-
administration of 25 and 50 mg pCAG-GM resulted in a
significant reduction of specific JEV Ab titers (p,0.01), whereas
mice co-inoculated with 10 mg pCAG-GM had less of an effect on
anti-prM-E Ab responses (p,0.05), indicating that the suppressive
effect of GM-CSF was dose-dependent. Meanwhile, the levels of
the IgG1 and IgG2a subtypes were also measured by ELISA. The
results showed that co-administration with high doses of pCAG-
GM (25 and 50 mg) generated lower levels of IgG2a than IgG1
and a lower IgG2a/IgG1 ratio with 0.55460.041 and
0.61360.045, respectively, compared with that (0.76560.055) of
the low dose (10 mg) group (Figure 6C). However, there was no
significant difference in IgG2a levels between high doses (25 and
50 mg) groups and lower dose (10 mg) group.
The suppressive effect of pCAG-GM was timing-
dependent
To determine if the suppressive effect of GM-CSF was
associated with the timing of the pCAG-GM injection, BALB/c
mice were inoculated with 50 mg pCAG-JME+50 mg pCAG-GM
Figure 4. Mouse-specific serum IgG subclass responses to JEV DNA immunization were determined by ELISA. Sera (1:200) were
collected from vaccinated mice (n=10) three weeks post-immunization. Values reported above for each group are the mean 6 SD of the OD at
492 nm. The solid bars represent the IgG1 subtype, and the hollow bars represent the IgG2a subtype. The IgG2a/IgG1 ratios of three groups are
0.61360.045, 0.73460.057 and 0.95460.062, respectively.
doi:10.1371/journal.pone.0034602.g004
Figure 5. Protective immunity elicited by JEV-prM-E DNA
vaccines. Mice (n=8) were challenged with a dose of 50 LD50 of
JEV (Beijing-1) three weeks post-immunization followed by daily
monitoring for 21 days, and the percentage of survivors was calculated
(p,0.05, pCAG-JME+pCAG-GM group vs. pCAG-JME+pCAGGSP7 group,
log-rank test).
doi:10.1371/journal.pone.0034602.g005
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ahead or 1 day after pCAG-JME inoculation. Three weeks
following the three immunizations, the levels of anti-JEV prM-E
Ab in the sera were analyzed by ELISA. As shown in Figure 7A,
co-administration of pCAG-GM before, together with or after
pCAG-JME delivery significantly suppressed the anti-JEV prM-E
Ab titers (p,0.05). Mice receiving pCAG-GM 1 or 3 day(s) before
pCAG-JME delivery had slightly lower anti-JEV titers than that in
mice receiving pCAG-GM coincident with pCAG-JME. However,
when pCAG-GM was given 1 day after pCAG-JME delivery, the
Ab titers increased more than 2-fold compared to those obtained
with giving pCAG-GM 1 or 3 day(s) ahead of pCAG-JME
inoculation. This result indicated that pretreatment with pCAG-
GM led to greater effects on the immune response induced by
pCAG-JME.
Figure 6. The suppression of Ab responses by the GM-CSF plasmid was dose-dependent. (A) Mice (n=5) were inoculated with various
dosages of pCAG-GM (10, 25 and 50 mg) or pCAGGSP7 (50 mg) without booster and the expression levels of GM-CSF in the undiluted sera were
monitored by ELISA at pre-inoculation and 1, 3, 5, 7 and 9 day(s) post-inoculation. The expression levels of GM-CSF are shown as the mean
concentration with a SD (p,0.01, one-way ANOVA test). (B, C) Mice (n=5) were immunized with pCAG-JME (50 mg) plus various doses of pCAG-GM
(10, 25 and 50 mg) or pCAGGSP7 (50 mg) three times at three-week intervals. Mice treated with 100 mg pCAGGSP7 served as the control. Three weeks
after the final immunization, serum samples were collected and the Ab immune response was detected by ELISA. The levels of specific anti-JEV-prME
Abs are shown as GMT (*, p,0.05; **, p,0.01, vs. pCAG-JME 50 mg+pCAGGSP7 50 mg group, one-way ANOVA test) (B). The levels of JEV-specific
serum (1:200) IgG subclasses are shown as the OD value (C), and the solid bars represent the IgG1 subtype, the hollow bars represent the IgG2a
subtype. The IgG2a/IgG1 ratios of five groups are 0.61360.045, 0.55460.041, 0.76560.055, 0.73460.057 and 0.95460.062, in turn.
doi:10.1371/journal.pone.0034602.g006
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pCAG-GM 3 days before pCAG-JME immunization resulted in
high IgG2a titers, indicating a primary Th1-biased response
(Figure 7B). Injection of pCAG-GM 1 day prior to pCAG-JME
delivery induced both a Th1 and a Th2 response. When pCAG-
GM was inoculated simultaneously with or 1 day following the JEV
DNA vaccination, the ratio of IgG2a/IgG1 gradually recovered to
that of the pCAG-JME+pCAGGSP7 group, indicating an en-
hancement of Th2 immunity. The IgG1 and IgG2a levels in group
pCAG-GM 3 days, and the IgG2a level in group pCAG-GM 1 day
before pCAG-JME immunization were significantly different from
that of other groups (simultaneously with, 1 day later and pCAG-
JME+pCAGGSP7). The IgG2a/IgG1 ratios of these groups were
1.50960.141, 1.09460.099, 0.61360.045, 0.66260.065 and
0.73460.057, respectively. These results suggested that the timing
of GM-CSF co-administration significantly altered the subtype of
the resulting Th response. Pretreatment with the pCAG-GM
adjuvant indeed favored a shift to Th1 over Th2.
Co-inoculation of pCAG-GM modulated cytokine
production
The levels of IFN-c, IL-2, IL-4, IL-17 and IL-10 cytokines
secreted bysplenocytesofmiceimmunizedwith plasmid DNAupon
stimulation with the JEV antigen were examined by enzyme-linked
immunospot (ELISPOT) assay. The results showedthat the levels of
IFN-c, IL-2,IL-4and IL-17 inthepCAG-JME+pCAGGSP7group
were significantly higher than those in the vector control group
(Figure 8). However, the GM-CSF adjuvant dramatically decreased
the secreted levels of IFN-c (p,0.05), IL-2 (p,0.01), IL-4 (p,0.05)
and IL-17 (p,0.01) when compared with the mice received pCAG-
JME without pCAG-GM. Notably, in contrast, IL-10 production
was significantly elevated in the pCAG-JME+pCAG-GM group
(p,0.01) compared with the pCAG-JME+pCAGGSP7 and vector
control groups. Because IL-2 and IFN-c are markers of the Th1
response, IL-4 expression is used as a marker of the Th2 response,
and IL17 is defined as a predominant marker of the Th17 pathway
[27], these results indicated that the Th1-, Th2- and Th17-like
immune responses were all stimulated by i.m. administration of the
JEV prM-E DNA vaccine, whereas they were significantly inhibited
by the pCAG-GM adjuvant. Interestingly, a dramatically higher
level of IL-10, a inhibitory cytokine, was observed in the mice co-
treated with pCAG-GM, which may suggest that the suppressive
effect by pCAG-GM may be associated with the degree of DC
maturation and/or generation of Tregs, as semimature DCs are
involved in the immunogenic tolerance caused by GM-CSF via an
increase in the induction of IL-10-producing Tregs [18,28].
Co-administration of pCAG-GM influenced DC
maturation and induced the generation of Tregs but not
MDSCs
To investigate if the characteristics of immature DCs were
altered by GM-CSF plasmid co-inoculation, the levels of
Figure 7. The suppressive effect of the GM-CSF plasmid on Ab responses was timing-dependent. Mice (n=5) were vaccinated with
50 mg pCAG-JME with 50 mg pCAG-GM or pCAGGSP7. The numbers beneath the x-axis indicate the timing of immunization. The 0 indicates that the
GM-CSF plasmid was given with pCAG-JME simultaneously, 23o r21 indicates that the plasmid was given 3 days or 1 day ahead of pCAG-JME
delivery, respectively, and 1 indicates that pCAG-GM was given 1 day after pCAG-JME vaccination. Mice treated with 100 mg pCAGGSP7 served as the
control. All animals received two booster doses at three-week intervals. Three weeks after the final immunization, serum samples were collected and
the Ab immune response was detected by ELISA. The levels of specific anti-JEV-prME Abs are shown as GMT (A). (*, p,0.05; **, p,0.01, vs. pCAG-JME
50 mg+pCAGGSP7 50 mg group, one-way ANOVA test). The levels of JEV-specific serum (1:200) IgG subclasses are shown as the OD value (B), and the
solid bars represent the IgG1 subtype, the hollow bars represent the IgG2a subtype (*, p,0.05; **, p,0.01, vs. 0d, 1d or pCAGGSP7 50 mg groups;
one-way ANOVA test). The IgG2a/IgG1 ratios of these six groups are 1.50960.141, 1.09460.099, 0.61360.045, 0.66260.065, 0.73460.057 and
0.95460.062, in turn.
doi:10.1371/journal.pone.0034602.g007
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including CD40, CD80, CD86 and MHC II, of DCs in peripheral
blood were evaluated by fluorescence-activated cell sorting
(FACS). As shown in Figure 9, the expression levels of maturation
surface markers of DCs were similar in the pCAG-JME+p-
CAGGSP7 and the vector control groups, but the markers were
markedly down-regulated in the group co-immunized with pCAG-
GM. This result indicated that the JEV prM-E DNA vaccine did
not accelerate the maturation of DCs, whereas the co-injection of
pCAG-GM significantly inhibited the maturation process of DCs.
To examine if co-inoculation with the GM-CSF plasmid
affected the relative numbers of Tregs, the surface expression of
CD3e, CD4 and CD25 and the intracellular expression of the
most accepted marker of Tregs, Foxp3, were detected in mouse
peripheral blood cells by FACS. As shown in Figure 10, a
significant increase in the percentage of CD3e
+ CD4
+ CD25
+
Foxp3
+ Tregs was observed in the group co-immunized with
pCAG-GM and pCAG-JME when compared to the pCAG-
JME+pCAGGSP7 and vector control groups. This result was
consistent with the FACS analysis for the maturation of DCs,
indicating that the low expression of the major costimulatory
molecules of DCs might induce the generation of Tregs, turn off
activated T cells and result in immune tolerance [20].
To further investigate the role of MDSCs in the immune
tolerance induced by the GM-CSF plasmid, the surface expression
levels of mouse CD11b and Gr-1 on peripheral blood cells were
analyzed by FACS. Unfortunately, there was no obvious difference
in the percentages of CD11b
+ Gr-1
+ MDSCs (data not shown) in
pCAG-JME-immunized mice with or without pCAG-GM. This
result demonstrated that MDSCs were not involved in the
induction of the immune suppression by the GM-CSF plasmid
under the experimental conditions in this study, although CD11b
+
Gr-1
+ MDSCs have a close relationship with immature DCs and
Tregs.
The GM-CSF plasmid adjuvant did not affect the
immunogen expression of plasmid DNA vaccine
To evaluate if co-inoculation with pCAG-GM affected the
immunogen expression of the JEV DNA vaccine, the sera were
collected at pre-inoculation and at 1, 3, 5, 7, 14 and 21 day(s) post-
inoculation, and the level of JEV prM-E protein in the sera was
measured by ELISA. As shown in Figure 11, the mice immunized
with pCAG-JME either with or without pCAG-GM had
significantly increased amounts of JEV prM-E protein. The
elevated level of prM-E expression was observed as early as 3 days
following vaccine inoculation and reached a peak on day 5,
followed by a decrease. Expression was detected until day 14
following vaccination. No obvious differences were observed
between these two groups. This result suggested that the GM-
CSF plasmid adjuvant did not affect the immunogen expression of
the DNA vaccine plasmid in this study.
Discussion
Co-inoculation of the GM-CSF plasmid depressed both
the humoral and cellular immune responses induced by
JEV DNA vaccines expressing prM-E
As a potential cytokine adjuvant of DNA vaccines, GM-CSF
has received considerable attention for its essential role in the
recruitment of APCs and the differentiation, growth and
maturation of DCs. In addition, as a well-recognized regulator
of hematopoiesis, GM-CSF is commonly administered in clinical
practice to treat neutropenia and enhance leukocyte activity.
However, our recent study of a JEV DNA vaccine [10] showed
that co-inoculation of the GM-CSF plasmid significantly sup-
pressed the specific IgG response and resulted in decreased
protection against JEV challenge. These data raise the concern
that the use of GM-CSF as an adjuvant or as a treatment agent
might be harmful because GM-CSF can impair the vaccine-
induced or anti-tumor immune responses under conditions that
remain unclear. In this study, we first confirmed the suppressive
effect of the co-administration of a GM-CSF plasmid on the
immune response induced by a JEV DNA vaccine and the
properties of this suppression. It was found that the plasmid
expressing the JEV protein prM-E could elicit high levels of JEV-
specific Abs, with a GMT of 1:14,700, and a 100% survival rate in
animals (Figures 1, 2 and 5), whereas mice co-inoculated with the
GM-CSF plasmid and the JEV prM-E plasmid had a low level of
immune response, with a low end-point Ab titer of 1:1838, and a
low protective rate (50%). This result indicated that the co-
immunization of the GM-CSF plasmid did not enhance the
vaccine-induced specific Ab response, nor did it provide sufficient
protective immunity against JEV challenge.
The effects of the GM-CSF plasmid on the cellular immune
response were also investigated in this study, and the levels of IFN-
c, IL-2, IL-4, IL-17 and IL-10 cytokines secreted by splenocytes
from immunized mice were examined by ELISPOT. High levels
of IFN-c, IL-2, IL-4 and IL-17 were observed in the pCAG-
JME+pCAGGSP7 group, whereas the GM-CSF plasmid adjuvant
markedly inhibited the secreted levels of IFN-c, IL-2, IL-4, and IL-
17 (Figure 8). These cytokines represent the major factors involved
Figure 8. Analysis of the effect of pCAG-GM on splenocyte-
secreted cytokines. Splenocytes were isolated from mice (n=6) three
weeks after the final immunization. The levels of cell-produced IFN-c, IL-
2 and IL-4 (A), IL-17 and IL-10 (B) following stimulation by concentrated
JEV proteins for 48 h were measured by ELISPOT assays. The numbers
of cytokine-positive cells are expressed as spot-forming units (SFU)/
5610
5 cells after background subtraction (*, p,0.05; **, p,0.01, one-
way ANOVA test).
doi:10.1371/journal.pone.0034602.g008
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Therefore, the results indicated that the pCAG-GM adjuvant
significantly inhibited all the Th1-, Th2- and Th17-like immune
responses elicited by the DNA vaccine.
It is noteworthy that a significantly elevated level of IL-10 was
observed in the pCAG-GM co-treated mice in this study
(Figure 8B). This was consistent with a study of the suppressive
effect of GM-CSF on the progress of autoimmune disease, in
which IL-10 levels were significantly increased in GM-CSF-treated
mice, and IL-10 was shown to be essential for disease suppression
in these animals [28]. It is known that IL-10 is not only a marker of
the Th2 response but also acts as an inhibitory cytokine involved
in the modulation of DC maturation and the generation of Tregs
[29]. Accordingly, in our study, IL-10 may be associated with
immunogenic tolerance caused by GM-CSF via the increased
induction of Tregs and immature DCs (see below).
Furthermore, JEV-specific IgG isotype Ab levels were also
determined, and the control group mice had similar levels of
IgG2a and IgG1 in the sera, whereas reduced IgG2a/IgG1 ratios
were observed in both groups of immunized mice with or without
pCAG-GM (Figure 4). Because IgG2a and IgG1 represent Th1
and Th2 immune cell types, respectively, this finding indicated a
bias toward the Th2 immune response to JEV prM-E proteins.
However, the use of the GM-CSF adjuvant caused an insignificant
change in IgG1 level and a little decreased level of IgG2a.
Consistent with the results of cytokines and specific IgG titers, this
result suggested that co-injection of the GM-CSF plasmid could
suppress both the humoral and cellular immune responses induced
by JEV prM-E DNA vaccines.
In agreement with our findings, another study of an JEV DNA
vaccine [30] also demonstrated that the co-administration of an
IL-12-expressing plasmid could be detrimental to the immune
responses elicited by the DNA vaccine encoding the envelope (E)
protein of JEV. Similarly, in another study of an HIV-1 DNA
vaccine [11], the GM-CSF-encoding plasmid was reported to fail
to augment the immune responses induced by a plasmid encoding
HIV-1 gp120, and an elevated level of type I IFN in the local site
of inoculation was associated with the inhibitory effect of the GM-
CSF plasmid in vivo. Recently, opposite immune functions of
GM-CSF administered as a vaccine adjuvant in cancer patients
was reported [31]. Moreover, GM-CSF has been used to
effectively induce immune tolerance in animal models of
experimental autoimmune disease, including myasthenia gravis
and diabetes, and the beneficial effect of GM-CSF therapy in these
diseases was shown to be mediated through the promotion of
tolerogenic DCs and the expansion of Tregs [22,23].
Figure 9. Analysis of the suppressive effect of pCAG-GM on DC maturation. 100 ml peripheral blood from immunized mice (n=6) was
stained with fluorescently conjugated mouse mAb to detect the expression of the surface markers CD11c, CD40, CD80, CD83 and MHC II on DCs. (A)
Representative data from the FACS analysis of peripheral blood DCs from the immunized mice on the 8th day after the final vaccination. The
percentage of double-positive cells is indicated in the top of right corner. (B) The bar graph shows the mean percentage with a SD of CD11c
+ cells
expressing maturation markers in different groups (*, p,0.05; **, p,0.01; one-way ANOVA test).
doi:10.1371/journal.pone.0034602.g009
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DNA vaccine studies in which GM-CSF acted as the adjuvant and
could enhance immune responses via several mechanisms,
including the activation of granulocytes, macrophages and natural
killer T cells and the promotion of the local recruitment and
maturation of DCs, which likely led to the improvement of tumor
antigen presentation to T lymphocytes [32,33,34].
These reports demonstrate contrasting GM-CSF-induced
effects: on one hand, because GM-CSF plays important roles in
the enhancement of immune responses, it has been recommended
as a cytokine adjuvant in some vaccines and as a treatment to
‘‘boost’’ the immune response in infection or cancer patients. On
the other hand, GM-CSF can induce immune tolerance and has
been used to treat autoimmune diseases. Although we cannot
completely explain this apparent paradox, it is thought to be
related to several factors, including the immunogen, the dose,
which may be an important determinant, and the timing of GM-
CSF administration. Further studies are needed to investigate the
mechanisms underlying the suppressive phenomenon and how
GM-CSF can be used safely in clinic.
The immune suppression of the GM-CSF plasmid was
dose- and timing-dependent and could be related to the
immunogenicity of the antigens
The suppressive effect of GM-CSF has been considered to be
associated with the doses of GM-CSF used in the study, and a
large amount of GM-CSF might cause immune suppression. To
confirm this, we used different doses of pCAG-GM to co-
immunize mice. Unsurprisingly, it was demonstrated that the
expressed levels of GM-CSF were closely related to the inoculated
Figure 10. Analysis of the amplifying effect of pCAG-GM on Tregs. 100 ml peripheral blood from immunized mice (n=6) was stained with
fluorescently conjugated mouse mAbs to detect the surface expression of CD3e, CD4 and CD25 and the intracellular expression of Foxp3. (A)
Representative data from the FACS analysis of peripheral blood CD4
+CD25
+Foxp3
+ Tregs from the immunized mice three weeks after the final
vaccination. The percentage of double-positive cells is indicated in the top of right corner. (B) The bar graph shows the mean percentage with a SD of
CD4
+CD25
+ Foxp3
+ Tregs among CD4
+ T cells in different groups (**, p,0.01, one-way ANOVA test).
doi:10.1371/journal.pone.0034602.g010
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doses of GM-CSF plasmid (from 10 to 50 mg), and the highest dose
of pCAG-GM (50 mg) resulted in the lowest specific JEV Ab titer
(Figure 6), suggesting that suppressive effect of GM-CSF was dose-
dependent.
Recent studies reported by Parmiani et al [31] concluded that
the dose of GM-CSF used as an immune adjuvant was paramount
in clinical trials. Relatively lower doses (40–80 mg for 1–5 days in
vaccinated cancer patients) could elicit an immune response,
whereas higher doses (100–500 mg) showed no advantage, even
lost its efficacy and involved in its clinical implications resulted in
immunosuppression in vivo under certain circumstances. In other
words, high dose of GM-CSF was likely associated with side effects
and immunotoxicity. Serafini et al [35] reported that the expressive
level of GM-CSF at 58 pg/ml in mice sera was low enough in
enhancing the immune response induced by the tumor vaccine,
while the serum level of GM-CSF at 206 pg/ml showed an
inhibitory role. However, in our study, the peak serum
concentration of GM-CSF from the lowest dose (10 mg) group
was 46.46 pg/ml, it still caused a markedly suppressive effect in
JEV DNA vaccine. Thus we proposed that the expressed level of
GM-CSF with lowest dose used in this study was likely to exceed
the maximum range required for enhancement of the JEV DNA
vaccine. Taken together, the dose of GM-CSF was thought to be a
crucial factor in determining the strength and state of vaccine-
induced immune responses but not the unique one and other
factors such as experimental condition, immunogen and admin-
istration timing were also involved in.
Moreover, to determine if immune suppression of GM-CSF was
associated with the timing of the treatment, pCAG-GM was
inoculated prior to or after pCAG-JEM vaccination. Mice injected
with pCAG-GM before pCAG-JME delivery had a strong
inhibition of Ab titers compared with mice in which pCAG-GM
was simultaneously given with pCAG-JME. When pCAG-GM
was given 1 day later, the inhibitory effect of GM-CSF was slightly
weaker, and the anti-JEV Ab titer showed an increased trend but
was still markedly lower than that in the group given pCAG-
JME+pCAGGS7 (Figure 7). This result implied that the
pretreatment with GM-CSF had significant effects on the
vaccine-induced immune response. Delaying the addition of
GM-CSF resulted in progressively less inhibition. Interestingly,
changes in the IgG2a/IgG1 ratio seemed to be closely associated
with the time of delivery, and the inoculation with pCAG-GM 3
days before pCAG-JME delivery resulted in a high IgG2a titer and
high IgG2a/IgG1 ratio. The strength of the IgG2a and IgG1
responses was similar when pCAG-GM was injected 1 day prior to
pCAG-JME delivery. High IgG1 titers and the IgG2a/IgG1 ratio
gradually recovered to that of the pCAG-JME+pCAGGSP7 group
when pCAG-GM was given simultaneously with or 1 day after the
pCAG-JME vaccination. These results suggested that the
pretreatment with pCAG-GM elicited a response that was
primarily biased towards Th1, whereas simultaneous co-inocula-
tion or post-treatment enhanced Th2 immunity. This was not
consistent with another study [36], in which pretreatment with the
GM-CSF plasmid primarily elicited a Th2 response and the
simultaneous injection of the GM-CSF plasmid with the DNA
vaccine activated both a Th1 and a Th2 response. When GM-
CSF was administered 3 days after DNA vaccination, there was a
predominant enhancement of Th1 immunity. We cannot explain
this contradiction by our results, and it may be related to the
experimental conditions. Nevertheless, our results and those of
others suggested that the timing of GM-CSF co-administration
also influenced immune responses and markedly altered the
phenotype of the resultant Th response.
In addition, to investigate if the immune suppression of pCAG-
GM was related to the JEV prM-E protein, pCAG-GM was also
co-administered with pCAG-D1ME, pCAG-D2ME, pCAG-
HCV-C or pCAG-HCV-E1. Interestingly, a slight inhibitory
effect on the Ab responses induced by the DENV DNA vaccines
was observed, whereas pCAG-GM co-inoculation showed an
enhancing trend in HCV-C- or HCV-E1-induced immune
responses (Figure 2). We cannot explain why GM-CSF played
opposite roles in the immune responses induced by different
vaccines, but the diverse immunogenicity of these antigens was
thought as one of the key reasons. It is known that both the prM-E
proteins of DENVs, JEV and C, E1 proteins of HCV have
different immunogenicities and that the properties of the immune
responses they induce are different. For example, the prM-E
protein of JEV is a strong immunogen, and JEV infection
predominantly induces a humoral immune response, whereas
DENV and HCV infections predominantly induce cellular
immune responses, although Ab reactions are also involved in
the immune responses. As known, for various antigen peptides or
epitopes with different immunogenicity, the different antigen
recognition and presentation might define the immunologic
outcome. Moreover, served as the professional APC, DCs
maturation was found to be influenced by the co-delivery of
GM-CSF. Therefore, the different effects of GM-CSF in different
but related vaccine antigens might be also associated with the
modulation of antigen recognition and presentation pathways.
Further studies are required for investigating which kind of antigen
GM-CSF would enhance in the antigen presentation.
Together, the above results suggested that the immune
suppression of plasmid GM-CSF was dose- and timing- dependent
and may be closely related to the immunogenicity of the antigen,
further indicating that the roles of GM-CSF have complex
versatility. Therefore, caution should be exercised in the safe use of
GM-CSF as an adjuvant in vaccination trials or as a therapeutic
agent in cancer or transplantation patients. In further studies, it
will be important to establish a dose range and time schedule of
GM-CSF co-administration with different DNA vaccinations, i.e.,
to determine under which conditions GM-CSF is able to activate
Figure 11. Kinetics of the expression of the JEV DNA vaccine
immunogen. Mice (n=5) were immunized with plasmids without
booster. JEV prM-E protein expression was measured by ELISA in the
undiluted sera collected at pre-inoculation and 1, 3, 5, 7, 14 and 21 days
post-inoculation. Data are expressed as the mean values of OD with a
SD.
doi:10.1371/journal.pone.0034602.g011
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or induce immune tolerance, in order to meet the demands of
various clinical application.
Immature DCs and Tregs but not MDSCs were involved
in the immunosuppression induced by GM-CSF
Tolerance can be defined as the inability of a host to respond to
antigens, and it can be generated centrally or peripherally. A
number of mechanisms, including antigen expression, DC
maturation, Tregs and MDSCs generation, may contribute to
the tolerance or immune suppression caused by cytokine
adjuvants. In our study, it was hypothesized that the suppression
might be due to the reduction in JEV antigen expression caused by
GM-CSF expression; therefore, serum levels of the JEV prM-E
protein were determined by ELISA. However, there were no
significant differences in the serum protein levels between the two
groups of mice inoculated with or without pCAG-GM (Figure 11),
indicating that the treatment with GM-CSF did not affect JEV
prM-E expression and secretion; thus, the suppression could
mainly result from other factors. DCs have been shown to
contribute to T-cell tolerance, and the immature developmental
stages of DC differentiation were believed to induce T-cell anergy
or Tregs. whereas the DCs that can transform into mature DCs
under exposure to activating stimuli were thought to be
immunogenic, with the capability of promoting an effector T cell
response [18,20,37]. Current evidence indicates that the immu-
nogenic or tolerogenic function of DCs is largely determined by
differentiation status, and GM-CSF plays an essential role in the
promotion of the differentiation. Therefore, we investigated if
there was enhancement of immature DCs in the blood after
pCAG-GM co-inoculation. As expected, the expression of the
mouse DC surface markers CD11c, CD40, CD80, CD83 and
MHC II was drastically down-regulated in the group co-
immunized with pCAG-GM (Figure 9), indicating that the co-
injection of pCAG-GM significantly inhibited the maturation
process of DCs.
Recent studies have shown that DCs may exert their tolerogenic
functions through the generation of Tregs, and Foxp3 is currently
the best available marker for these cells [37,38]. Accordingly, a
significant expansion in the population of CD4
+CD25
+Foxp3
+-
Tregs was observed in mice co-inoculated with GM-CSF
(Figure 10), strongly indicating a possibility that GM-CSF
treatment mobilized Tregs via tolerogenic DCs. Moreover, we
analyzed cytokine production by assessing their expression levels in
splenic lymphocytes isolated from treated animals. GM-CSF-
treated mice had an increased expression of IL-10 (Figure 8) but
not TGF-b (data not shown). It is known that IL-10 and TGF-b
are important inhibitory cytokines, and this result suggested that
the immunosuppression induced by GM-CSF was likely related to
IL-10 but not TGF-b. In fact, IL-10 can be secreted by many
immune cells, including CD4
+CD25
+ Tregs and DCs, and the
function of DCs, Tregs and IL-10 are interrelated. Immature DCs
which can produce IL-10 and induce IL-10-producing Tregs are
capable of inducing immunogenic tolerance [28,29,39,40]. How
these cells interact is not clear and will be the focus of further
studies.
In addition, more recent studies have demonstrated that
MDSCs act as a new mechanism of immune suppression and
are characterized as CD11b
+Gr-1
+ in mice. It has been accepted
that MDSC expansion and activation are likely controlled by GM-
CSF, and high doses of GM-CSF-producing vaccines impair the
immune response through the recruitment of MDSCs [41]. In this
study, we also analyzed the percentage of CD11b
+Gr-1
+ MDSCs
in blood after co-immunization with pCAG-GM. Unexpectedly,
there was no significant difference in the number of MDSCs in
pCAG-JME-immunized mice with or without pCAG-GM (data
not shown), implying that MDSCs were not involved in the
induction of immune suppression by the GM-CSF plasmid in this
study, and GM-CSF treatment may directly affect the maturation
state of DCs and induce the generation of Tregs, thereby resulting
in immune suppression.
A study by Serafini [35] demonstrated that CD11b
+Gr-1
+
MDSCs were responsible for the induction of T-cell dysfunctions
and were associated with the temporary impairment of T-
lymphocyte reactivity. Additionally, Parmiani [31] analyzed
studies dealing with the immune adjuvant activity of GM-CSF
both in animal models and in clinical trials and concluded that
GM-CSF may increase the vaccine-induced immune response
when repeatedly administered at relatively low doses, whereas an
opposite effect was often reported at high doses. According to
these results, the lack of obvious changes in MDSC numbers in
our study may be associated with the dose of GM-CSF used in our
study, which may have failed to achieve a systemic concentration
high enough to activate MDSCs.
In summary, we have shown that co-inoculation of the GM-
CSF plasmid suppressed both cellular- and Ab-specific responses
induced by JEV prM-E DNA vaccination. Additionally, Th1
immune responses were more sensitive to GM-CSF treatment
than was Th2. The immune suppression was dose- and timing-
dependent and related to the antigens. This effect was accompa-
nied by an increase in IL-10, the mobilization of DCs with a
tolerogenic phenotype and an expansion of Tregs but not MDSCs,
suggesting that immature DCs, IL-10 and Tregs are involved in
the immune suppression induced by co-inoculation of JEV prM-E
DNA with pCAG-GM. The results provided useful information
not only for further understanding of the versatility of GM-CSF
function but also for development of safe clinical applications.
Moreover, as already discussed, GM-CSF has opposite effects on
the immune response induced by different DNA vaccines under
different mechanisms, leading either to the amplification or down-
regulation of the immune reactions. In the near future, it will be of
paramount importance to establish under which conditions GM-
CSF enhances the immune response or induces immune
suppression to optimize its potential clinical use as a vaccine
adjuvant or as a therapeutic agent.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the national guidelines for the use of animals
in scientific research ‘‘Regulations for the Administration of Affairs
Concerning Experimental Animals’’. The protocol was also
approved by the Animal Care and Use Committee of Chinese
Capital Medical University (Permit Number 2009-X-870). All
surgeries were performed under diethyl ether anesthesia, and all
efforts were made to minimize suffering.
Mice, cells and viruses
Female inbred BALB/c mice were purchased from the
Laboratory Animal Center of the Academy of Military Medical
Sciences (Beijing, China) and maintained at specific-pathogen-free
conditions.
Aedes albopictus cells (C6/36, ATCC CRL-1660) were grown at
28uC in RPMI 1640 (GIBCO, USA) supplemented with 10% fetal
bovine serum (FBS). African green monkey kidney cells (Vero,
ATCC CRL-1586) were grown at 37uC in Minimal Essential
Medium (GIBCO, USA) supplemented with 5% FBS.
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DENV2 (TR1751 strain) were propagated in C6/36 cell cultures
and stored at 270uC until use. Virus titers were determined by the
standard plaque assay on Vero cells under 1.3% methylcellulose
overlay medium.
Plasmids
The eukaryotic expression vector pCAGGSP7, containing a
ubiquitously strong b-actin promoter and allowing efficient
selection for transfectants that express foreign genes at high levels
[42], was a parental plasmid used for the construction of DNA
vaccines or the adjuvant plasmid and served as a control in this
study.
The pCAG-JME DNA vaccine was constructed for the
expression of JEV prM-E using the vector pCAGGSP7. Briefly,
genomic RNA of JEV was extracted from JEV (Bejing-1)-infected
C6/36 cells and served as a template for RT-PCR. The JEV prM-
E fragment containing the prM signal sequence (spanning
nucleotides 408 to 2477) obtained by RT-PCR was digested with
the Xho I and Not I restriction enzymes (MBI Fermentas, USA),
and subcloned into the multiple cloning site of pCAGGSP7.
Similarly, plasmids expressing prM-E of DENV 1 (nucleotides 365
to 2419) and DENV 2 (nucleotides 367 to 2421) were constructed
as described previously [43]. Plasmids expressing Core (nucleo-
tides 332 to 904) and E1 (nucleotides 851 to 1480) fragments of
HCV (HC-J4-91) were constructed following the same protocol.
The pCAG-GM plasmid encoding the murine GM-CSF
fragment was constructed following a previously described
protocol [10]. All gene sequences were obtained from GenBank
Database (http://www.ncbi.nlm.nih.gov/genbank).
The recombinant plasmids were confirmed by DNA sequencing
(TaKaRa, China) and double enzyme digestion, and the
expression of the plasmids was further confirmed by indirect
IFA in Vero cells. For immunization, the plasmid DNA was
extracted and purified from the transformed Escherichia coli strain
JM109 with an endotoxin-free plasmid extraction kit (Omega,
USA). The purified plasmids were then reconstituted in sterile
saline at a concentration of 1.0 mg/ml prior to use.
Experimental design
For DNA immunization, six-week-old female BALB/c mice
were pretreated with 50 ml 0.25% Lidocaine hydrochloride in
each quadriceps muscle two days before the first DNA inoculation
to enhance the muscle-cell uptake of plasmid DNA [44]. Groups
of mice were then injected intramuscularly three times at three-
week intervals with a mixture of 50 mg pCAG-GM and 50 mg
pCAG-JME or 50 mg pCAG-JME and 50 mg pCAGGSP7 in
100 ml sterile saline. Mice immunized with 100 mg pCAGGSP7
vector alone served as negative controls. Three weeks after the
final immunization, serum samples were collected for the
evaluation of the pre-challenge serum Ab titers.
To determine if the expression level of GM-CSF was related
with the inoculated amount, the mice were injected with various
doses of pCAG-GM (10, 25 or 50 mg) or pCAGGSP7 (50 mg) and
expressed levels of GM-CSF in the undiluted sera were measured
by ELISA at pre-inoculation and 1, 3, 5, 7 and 9 days post-
inoculation using mouse GM-CSF ELISA kit (R&D Systems,
USA), according to the manufacture’s direction. Five mice were
used for each dose and each time point.
To investigate if the GM-CSF effect was dose-dependent, five
groups of mice were immunized three times with the pCAG-JME
plasmid (50 mg) plus various doses of pCAG-GM (10, 25 or 50 mg)
or pCAGGSP7 (50 mg) at three-week intervals; anti-JEV-prM-E
Ab levels were then measured.
Similarly, to determine if the GM-CSF effect was timing-
dependent, mice were divided into six groups, and pCAG-GM was
injected 3 days or 1 day prior to, simultaneously or 1 day after
pCAG-JME immunization at the same location, and anti-JEV-
prM-E Ab levels were analyzed after two boosters.
To analyze if the effects of GM-CSF were antigen-dependent,
DNA immunizations were also performed using 50 mg pCAG-
D1ME, pCAG-D2ME, pCAG-HCV-C or pCAG-HCV-E1 with
50 mg pCAG-GM or pCAGGSP7 following the procedures as was
used for the pCAG-JME immunizations. After the final immuni-
zation, Ab titers were measured by ELISA.
For the protection test, three weeks after the third vaccination,
the mice were challenged intraperitoneally with JEV (Beijing-1) at
a lethal dose (50 LD50), followed by a sham intracerebral
injection, which served to increase the susceptibility of animals to a
central nervous system infection [45]. These mice were observed
daily for symptoms of viral encephalitis and mortality over 21
days.
Measurement of serum Ab levels by ELISA
Mice serum samples were collected by tail bleeding at different
time points and were tested for anti- JEV-prM-E Ab responses by
ELISA. Briefly, 96-well microtiter plates were coated overnight at
4uC with 10 mg/well of the concentrated virus proteins in 100 ml
carbonate-bicarbonate buffer (pH 9.6). The plates were washed
with phosphate-buffered saline (PBS) containing 0.2% Tween-20
(PBS-T) and blocked at 37uC for 1 h with PBS containing 1%
bovine serum albumin (BSA). Serum samples (100 ml) were then
added in two-fold serial dilutions (from 1:100) and incubated at
37uC for 1 h. After washing with PBS-T, the plates were incubated
at 37uC for 1 h with 100 ml goat anti-mouse IgG-HRP (1:3000,
KPL, USA) followed by the addition of the orthophenylene
diamine substrate solution for visualization. The reactions were
stopped by the addition of 2 M H2SO4. The OD values were
measured at 492 nm with an ELISA microplate reader (Thermo
Scientific, USA). The end-point titers were defined as the
reciprocal of the highest serum dilution that yielded an OD value
twice equal to or greater than the mean OD values of negative
control samples. For the measurement of the IgG subclasses, goat
anti-mouse IgG1-HRP and IgG2a-HRP (1:1000, SBA, USA) were
used as probes instead of IgG-HRP. Samples were tested in
duplicate and repeated at least twice.
In addition, the levels of anti-DENV-1 or DENV-2 Abs were
also detected with the same method, except DENV-1 or DENV-2
proteins replaced the JEV proteins as the antigens. The levels of
anti-HCV IgG were determined by ELISA kit (CSB, China)
following the manufacturer’s instructions.
Indirect Ab IFA
Anti-JEV Ab levels were also evaluated by indirect IFA three
weeks after the third inoculation. Briefly, monolayers of Vero cells
on sterile glass cover slips were infected with JEV for 21 h and
used as the antigen. Cells were washed with PBS, fixed with 4%
paraformaldehyde for 20 min, permeabilized with 0.2% Triton X-
100 in PBS for 5 min and then blocked with 1% BSA in PBS for
1 h. After incubation with DNA-immunized or normal mouse
serum (1:300) at 4uC overnight, the cell cover slips were washed
and incubated with FITC-conjugated goat anti-mouse IgG (1:200,
Immunotech, France) for 1 h. A cover slip incubated with mouse
anti-JEV E glycoprotein mAb (1:100, Abcam, USA) served as a
positive control. After washing, air-drying and mounting, the cells
were examined and photographed under a fluorescence micro-
scope (Olympus BX61, Japan).
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Splenocytes isolated from mice three weeks after the final
vaccination were subjected to the cytokine assay using IFN-c, IL-
2, IL-4 (BD Biosciences, USA), IL-10 and IL-17 ELISPOT sets
(R&D Systems, USA), according to the manufacturer’s instruc-
tions. In brief, splenocytes were aliquoted at 1610
6 per well into
96-well MultiScreen HTS Filter Plates (Millipore, USA) pre-
coated with anti-mouse IFN-c, IL-2, IL-4, IL-10 and IL-17
capture Abs, followed by stimulation with concentrated JEV
proteins at 5 mg/well for 48 h at 37uC. Simultaneously, the
splenocytes were co-cultured with concanavalin A as a positive
control or with RPMI 1640 medium alone as a negative control.
After incubation with biotin-conjugated secondary Abs and
streptavidin-HRP (for the IFN-c, IL-2 and IL-4 assay), single
cytokine-positive cells were visualized by adding AEC substrate
and counted using an ELISPOT reader (CTL, USA) with the
Immunospot image analyzer software version 4.0. For the IL-10
and IL-17 assay, streptavidin-AP and BCIP/NBT chromogen
were used instead of streptavidin-HRP and AEC substrate,
respectively.
FACS analysis of DC maturation in peripheral blood
DC maturation in peripheral blood was determined by a surface
marker staining assay with direct FACS analysis on the 8th day
after the final immunization. Rat anti-mouse CD16/CD32 mAb
(clone 2.4G2), PE-conjugated hamster anti-mouse CD11c (clone
HL3) mAb, APC-conjugated rat anti-mouse CD40 (clone 3/23),
CD80 (clone 16-10A1) mAbs, hamster anti-mouse CD86 (clone
GL1) mAb and subclass-matched control Abs were purchased
from BD Pharmingen (USA). APC-conjugated rat mAb to mouse
MHC II was purchased from Miltenyi Biotec (Germany).
100 ml blood taken by retro-orbital sinus puncture under
anesthesia with diethyl ether was collected into a heparin-coated
tube then blocked with rat anti-mouse CD16/CD32 mAb for
15 min at 4uC to eliminate non-specific binding to Fc receptors.
Cells were stained sequentially with purified anti-mouse CD11c,
CD40, CD80, CD86 and MHC II mAbs or subclass-matched
control Abs for 30 min at room temperature followed by
treatment with FACS Lysing Solution (BD Biosciences, USA) for
10 min, which lysed the erythrocytes and fixed other cells. Cells
were washed twice and resuspended in 200 ml 1% paraformalde-
hyde. Samples were run on a FACSCalibur flow cytometer (BD
Biosciences, USA) and analyzed using CellQuest Pro software
(version 6.0).
FACS analysis of CD4
+CD25
+Foxp3
+ Tregs in peripheral
blood
Three weeks after the final immunization, Tregs in peripheral
blood were analyzed by FACS. PerCP-conjugated hamster anti-
mouse CD3e (clone 145-2C11) mAb, FITC-conjugated rat anti-
mouse CD4 (clone RM4-5) mAb and APC-conjugated rat anti-
mouse CD25 (clone PC61) mAb were purchased from BD
Pharmingen (USA). PE-conjugated rat anti-mouse Foxp3 mAb
(clone FJK-16 s) was from eBioscience (USA).
100 ml heparinized blood were blocked with rat anti-mouse
CD16/CD32 mAb for 15 min at 4uC and then incubated with
anti-mouse CD3e, CD4, CD25 mAbs or their isotype controls for
surface marker staining. Subsequently, the cells were treated with
FACS lysing solution for 10 min. After washing, fixation,
permeabilization and a second blocking, intracellular labeling of
Foxp3 protein was performed by treating cells with anti-mouse
Foxp3 mAb for 30 min on ice in the dark. Cells were washed twice
and resuspended in 200 ml PBS containing 1% FBS followed by
immediate flow cytometric analysis.
FACS analysis of MDSCs in peripheral blood
100 ml heparinized blood was collected on day 5, 8 and 11 after
the final immunization followed by blocking and direct staining of
cell-surface markers. The following Abs purchased from BD
Pharmingen were used: PE-conjugated rat anti-mouse CD11b
(clone M1/70) mAbs, FITC-conjugated rat anti-mouse Ly6G and
Ly6C (clone RB6-8C5) mAbs and isotype control Abs.
Analysis of the expression level of JEV prM-E
The expression of JEV prM-E was detected by ELISA in mice
serum samples at pre-inoculation and 1, 3, 5, 7, 14 and 21 days
post-inoculation. The 96-well microtiter plates were coated
overnight at 4uC with 10 ml of each serum sample diluted with
90 ml carbonate-bicarbonate buffer (pH 9.6). The mouse anti-JEV
E glycoprotein mAb (Abcam, USA) was used as the primary Ab at
a 1:50 dilution. The other procedures were as the same as
described above.
Statistical analysis
Statistical analysis was performed using SPSS 17.0 software.
Survival curves were compared with log-rank test. Others were
compared using Student t test or one-way ANOVA test. Data
were considered statistically significant if p,0.05.
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